Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 14, 2018

Primary Completion Date

April 7, 2020

Study Completion Date

April 7, 2020

Conditions
Hypertension Pulmonary SecondaryHeart Failure, Right SidedHeart Failure With Normal Ejection Fraction
Interventions
DRUG

Levosimendan

A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion

DRUG

Matching Placebo

A sterile 2.5mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion

Trial Locations (16)

10021

New York Presbyterian Hospital-Weill Cornell Medicine, New York

10029

Ichan School of Medicine at Mount Sinai, New York

11030

North Shore University Hospital, Manhasset

15213

University of Pittsburgh Presbyterian Hospital, Pittsburgh

19104

Hospital of the University of Pennsylvania, Philadelphia

29425

Medical University of South Carolina, Charleston

45219

Christ Hospital, Cincinnati

53792

UW Health University Hospital, Madison

55455

University of Minnesota Medical Center, Minneapolis

55905

Mayo Clinic, Rochester

60611

Northwestern Memorial Hospital, Chicago

68198

University of Nebraska Medical Center, Omaha

94305

Stanford Healthcare, Stanford

02111

Tufts Medical Center, Boston

02114

Massachusetts General Hospital, Boston

02215

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Tenax Therapeutics, Inc.

INDUSTRY

NCT03541603 - Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF | Biotech Hunter | Biotech Hunter